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Background: Systemic juvenile idiopathic arthritis (SoJIA) is the most striking form of juvenile idiopathic arthritis.
The aim of our study was to evaluate the clinical responses and outcomes of children with SoJIA to IL-6 blockade
using two different tocilizumab (TCZ) treatment protocols designed for milder and more severe SoJIA patient
groups, and evaluate the possibility of achieving biologic-free remission.
Methods: Thirty-seven active SoJIA children who have failed treatment with corticosteroids and other DMARDs
were included in our retrospective study. TCZ doses were prescribed in two treatment approaches: every 2 weeks
TCZ dosing (Q2W) and every 4 weeks TCZ dosing (Q4W). The patients were assigned to these two groups by the
study physicians depending on the severity of the SoJIA disease as judged by each clinician.
Results: Thirty-three of the 37 children successfully completed the trial. TCZ was discontinued in 11patients during the
trial. Seven children achieved inactive disease and were allowed to stop the TCZ and 4 had severe adverse events
requiring drug cessation. Currently 7 patients continue to have TCZ-free remission [4/7 remission off-medication, 3/7still
on methotrexate (MTX)]. This mixed group had a median treatment duration of 1002 days. The children in remission off
of all medications, TCZ and MTX, had a median remission duration of 1162 days (ranged 932–1301 days).
Compared to the patients assigned to the Q2W TCZ treatment group, the patients assigned to the Q4W TCZ group
had a milder SoJIA course. The patients had higher levels of hemoglobin, total proteins, and serum albumins. They had
lower white blood cell counts (WBC), % granulocytes, CRP, ESR, ferritins, and LDH. These children had a lower frequency
of internal organ involvement, fewer relapses during TCZ treatment, and no macrophage activation syndrome
episodes.
Conclusions: Our experience with TCZ for SoJIA supports the excellent result of other studies. What may be novel is
our finding that thisIL-6 blockade with TCZ may be able to be utilized at a less frequent dosing schedule in mild SoJIA
compared to severe SoJIA. We discuss other factors that may increase the probability of a patient reaching TCZ-free
remission.
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Systemic-onset juvenile idiopathic arthritis (SoJIA) is the
most striking forms of juvenile idiopathic arthritis. This
challenging disease unchecked may lead to severe joint
disability and internal organ involvement and is frequently
associated with life-threatening complications such as
macrophage activation syndrome and amyloidosis [1].
There are typical SoJIA-related long-term adverse events
that have been noted for decades, both from the disease
and the treatment with corticosteroids. These include
anemia, Cushing’s syndrome, obesity, growth failure, osteo-
porosis with pathological fractures, aseptic bone necrosis,
hypertension as well as metabolic disturbances such as
hyperglycemia and dyslipidemia [2]. Due to the failure of
corticosteroids (CS) and DMARDs such as MTX to ad-
equately control SoJIA and difficult side effects of these
medications in many children, rheumatologists have re-
cently begun treating SoJIA patients with biologic medica-
tions despite the high cost of the drugs [3-7].
Biologic medications that provide blockade of interleukin-
1 (Il-1) and interleukin-6 (Il-6) appear to be most effective
current treatment of children with SoJIA in 2014. They
provide impressive control of SoJIA disease activity in
approximately 2/3’s of patients with SoJIA [3-6]. The
increasing use of these biologics had led to a dramatic
improvement in the short-term outcome of SoJIA patients
[4-7]. Unfortunately, Il- 1and IL-6 blockers in many coun-
tries are still not available and/or affordable. In our coun-
try, the IL-6 blocker is the only biologic drug available for
SoJIA management at this time.
Recent studies of the pathophysiology of SoJIA have
shown an important role for Il-6 in joint inflammation.
IL-6 also appears to have a major factor in systemic fea-
tures, such as rash, serositis, lymphadenopathy, and hepa-
tosplemomegaly [8-10]. Two major drug trials performed
initially by S.Yokota and co-workers in Japan and later in
USA and Europe (TENDER trial) have supported the effi-
cacy of IL-6 blockade in SoJIA [4-6]. Since IL-1 blockers
were unavailable in Russia at the time of this study and
tocilizumab (TCZ) was registered and approved for adults
with rheumatoid arthritis (RA), we have been able to use
TCZ off label for treatment of SoJIA, as the only option
for management of SoJIA in patients unresponsive to
other medications.
When we begun to use TCZ at our center, the data
about how frequently to administer TCZ for children with
SoJIA was limited. There was only data of S. Yokota’s
study, a study with a single TCZ infusion only, and studies
of TCZ administration in rheumatoid arthritis (RA) in
adults [4,5,11,12]. In the Japanese study, TCZ was admin-
istered every 2 weeks, while in adults with RA TCZ was
used every 4 weeks. P. Woo and co-workers showed the
8-week efficacy of single 8 mg/kg dose of TCZ. Later in
the CHERISH study and in a Japanese study about TCZin polyarticular-course JIA, TCZ was given every
4 weeks [13,14].
The aim of our study was to review our use of TCZ at
our clinic and evaluate the children’s clinical response to
IL-6 blockade. We used 2 TCZ treatment protocols and
evaluated outcomes including the optimal possibility of
achieving biologic-free remission.
Methods
Study design and patient selection
In our retrospective study, we reviewed the medical re-
cords of 37 children with active SOJIA. Diagnosis of SoJIA
was based on ILAR definitions [15]. TCZ was initiated in
each child at a dosage of 12 mg/kg if the child’s weight
was < 30 kg and 8 mg/kg if the weight was ≥30 kg. Active
disease was defined if patients had any clinical or labora-
tory abnormalities attributed to SoJIA. These features
included synovitis, an intermittently spiking fever, rash,
polyserositis, lymphadenopathy, hepatosplenomegaly, a C-
reactive protein (CRP) level >15 mg/l, and an erythrocyte
sedimentation rate (ESR) > 30 mm/hour.
The main inclusion criteria were:
1) An inadequate response or intolerance of DMARDs
and their combination;
2) Inability to sufficiently taper corticosteroids due to
flares of systemic features or synovitis or both;
3) The presence of corticosteroid-related side effects.
For assessment of efficacy we used the six variables of
the ACR core set for JIA: the number of joints with active
arthritis, the number of joints with limited range of mo-
tion, the physician’s global assessment of disease activity,
the parent’s global assessment of overall well-being and
physical function utilizing the Disability Index of the
Childhood Health Assessment Questionnaire, and the
erythrocyte sedimentation rate [16]. Fever was assessed by
measurement of the axillar temperature at least two times
a day. Only patients who achieved at least ACRPedi30 re-
sponse at day 14 could continue the study (improvement
of 30% or more in three or more of the six variables of the
ACR core set for JIA, with no more than 1 variable wors-
ening by more than 30% and absence of the fever). Simi-
larly, the ACRPedi70 response is defined as improvement
of at least 70% in at least three of the six core criteria for
JIA, with worsening of more than 30% in no more than
one criterion.
We used TCZ in 2 dose schedules: every 2 weeks
(Q2W) and every 4 weeks (Q4W). Each clinician made
the dose schedule decision based upon the severity of
disease, steroid-dependence, presence of MAS and organ
involvement. All patients that developed MAS immedi-
ately precede TCZ were treated only with Q2W TCZ.
Initially 29 patients were treated Q4W and 3 of them
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ening, defined as a clinical relapse or exacerbation after
the initial improvement). Only patients who had no
signs of flare, exacerbation, side effects or TCZ inefficacy
during Q4 week treatment could continue to receive
TCZ Q4W (n = 26).
Eight SoJIA patients with severe disease were initially
treated with Q2W TCZ. The number increased to eleven
patients who were considered to have severe SoJIA with
the addition of 3 children from the TCZ Q4W group
during the first 4 weeks or later of TCZ treatment. The
duration of study was from the times of the 1st and last
TCZ infusions of each patient.
The flow chart of our study is shown in Figure 1. The
protocol of this trial was approved by local Ethic
Committee of our University.
We collected the main SoJIA-related clinical and
laboratory data before 1st TCZ infusion. The diagnosis
of macrophage activation syndrome (MAS), was based
on the Ravelli criteria of 2002 and 2005 [17,18].
We evaluated all SoJIA-related laboratory data before 1st
TCZ infusion including hemoglobin (Hb), white blood cells
(WBC), % granulocytes count, platelets (PLT), Westergren
ESR, CRP, ferritin, lactate dehydrogenize (LDH) activity,
total serum protein, and albumin levels. Additionally, we
performed WBC and % granulocytes count testing in 1, 2
and 4 week after the 1st TCZ infusion.
The number of active joints was recorded at the be-
ginning of TCZ treatment. Inactive disease was defined
according to the Wallace criteria (2004): no joints with
active arthritis, no fever (body temperature ≤38°C),
and no rheumatoid rash, Inactive disease also required
serositis, splenomegaly, hepatomegaly or generalized
lymphadenopathy attributable to JIA, a normal ESR or
CRP, and a physician’s global assessment of disease
activity indicating no disease activity (i.e. best possibleFigure 1 Flow chart of the study.score ≤10 mm*) [19]. In our patients, a TCZ-free
remission meant that our patient had at least 12 month
course of TCZ, achieved the status of inactive disease,
successfully tapered off corticosteroids, stopped TCZ
and had at least 6 month period of inactive disease
after the last TCZ infusion.
Statistics
Descriptive statistics were reported in terms of medians
(Me) and interquartile ranges (IQRs) for continuous vari-
ables and in terms of absolute frequencies and percentages
for categorical variables. We utilized Mann–Whitney U-
test for comparison of quantitative variables in two groups
and chi-square test for comparison of qualitative data, or
the Fisher’s exact test in case of expected frequencies < 5.
The ability of each variable to discriminate the Q4W from
Q2W was evaluated with sensitivity and specificity ana-
lysis, AUC-ROC (area under receiver operating character-
istic) curve with 95% confidence interval (CI), calculating
odds ratio (OR) for detection of the best cut-offs of con-
tinuous variables. The higher values of OR of variables
interfere better with discriminatory ability. For laboratory
tests we used the AUC-ROC analysis with 95% CI. For
each categorical variable the analysis of sensitivity and
specificity was performed. We used the “best” threshold
obtained for the ROC curve analysis of our data because
they provide the most appropriate mean between sensitiv-
ity and specificity.
Survival analysis with for achievement of the TCZ-free
status due to remission as the event of interest was con-
ducted by means of the Kaplan-Meier method. Survival
curves were compared by the logrank test. Factors sig-
nificantly associated with time to achievement TCZ-free
status were then tested in a Cox proportional hazards
regression model. P < 0.05 was considered as statistically
significant. The software Statistica (release 6.0, StatSoft
Corporation, Tulsa, OK, USA), Biostat, and MedCalc
and were used for data analyses. P-values < 0.05 were
considered to indicate a significant difference.
Results
The main demographic parameters included the median
age (Me; IQR) of TCZ start of 10.2 years (range 6.0-12.8)
and the median delay from diagnosis to use of TCZ if
36.0 months (range 10.7-97.0). The median duration of
TCZ treatment was 665 (range 456–1000) days. Thirty-
three of 37 children (89.2%) successfully completed the
treatment program. In the beginning of the treatment of 4
patients, one died and 3 withdrew due to serious adverse
events and stopped the TCZ. Parameters were calculated
in groups that consisted of 37, 36 or 33 patients. Some pa-
tients included in the trial had few if any systemic features.
Some patients also may have had no active arthritis in the
trial. Both milder disease conditions may have been due to
Kostik et al. Pediatric Rheumatology 2015, 13:4 Page 4 of 9
http://www.ped-rheum.com/content/13/1/4disease course or concomitant treatment (e.g., corticoste-
roids ). Detailed data are in Table 1.
Macrophage activation syndrome (MAS) occurred be-
fore TCZ was in 12 children (32.4%). During the trial CS
was successfully discontinued in 21/26 (80.8) after a mean
of 66.0 days (range 43.0 – 93.0). CsA was discontinued in
10/20 (50.0%) after a mean of 53 days (range 25–85) after
achievement of improvement, MTX in 9/32 (28.1%)Table 1 Study population
Parameters Me (IQR), n = 37
Females, n (%) 21/37 (56.8)
Age of the start TCZ, years 10.2 (6.0-12.8)
TCZ delay, months 36.0 (10.7-97.0)
SoJIA related symptoms at the start of TCZ, n (%)
- fever 28 (75.7)
- rash 24 (73.0)
- hepatomegaly 20 (54.1)
- lymphadenopathy 13 (35.1)
- splenomegaly 11 (29.7)
- heart involvement 10 (27.0)
- interstitial lung disease 6 (16.2)
- CNS dysfunction 6 (16.2)
- coagulopathy with hemorrhage 4 (10.8)
Hemoglobin, g/dl 11.0 (10.3 – 12.1)
WBC, *109/l 11.9 (7.9 – 16.1)
Granulocytes, cells in 1 μl 7812.0 (5530.0 – 13202.0)
CRP, mg/l 35.0 (11.6 – 88.5)
ESR, mm/h 42.0 (22.0 – 54.0)
Platelets *109/l 361.0 (299.0 – 465.0)
Ferritin, mg/ml 197.0 (84.0 – 841.0)
LDH, U/l 513.0 (425.0 – 743.0)
Albumin, g/dl 3.0 (2.5 – 3.2)
Number of active joints at the start of TCZ 7.0 (2.0 – 22.0)
no active joints, n (%) 4 (10.8)
< 5 active joints, n (%) 13 (35.1)
≥5 active joints, n (%) 20 (54.1)
Treatment before TCZ administration:
- Corticosteroids, n (%) 26 (70.3)
- mean dose, mg/kg 0,73
- Methotrexate, n (%) 32 (86.5)
- mean dose, mg/m2/week 14,7
- Cyclosporine A, n (%) 20 (54.1)
- mean dose, mg/kg 4,2
Combination 18 (48.7)
MAS before TCZ administration, n (%) 12 (32.4)
*Pts # 27, 32 have developed infusion reaction and MAS coincidently; pt # 20
had only infusion reaction leads to TCZ discontinuation, Me – median,
IQR –interquartile ranges.patients after a mean of 11.5 months (range 3.8 – 25.6).
During the trial 11/33 (33.3%) patients accomplished the
status of being only on the monotherapy of TCZ.
Tocilizumab was discontinued in 11 patients during
the trial. The reasons for stopping TCZ were achieve-
ment of inactive diseases status, severe adverse events
and death. Inactive disease was reached in 12 patients,
and TCZ treatment was stopped in 7/33 (21.2%) chil-
dren. Severe adverse events (SAE) included infusion re-
actions and a diagnosis of early MAS. These problems
lead to withdrawal of TCZ treatment patients after the
2nd or 3rd infusions; three patients were from the Q2W
group and 1 case of infusion reaction was in the Q4W
group. Interestingly, 2 of these patients have developed
both infusion reaction and MAS at the same time. One
patient had an infusion reaction only. All infusion reac-
tions were stereotypical: chill, pallor, acrocyanosis, arter-
ial hypotension. After TCZ initiation, 5 (13.6%) of the
children developed MAS. All 5 had the MAS in their
past medical history immediately before 1st TCZ infu-
sion, so no new cases developed on TCZ. Two children
withdrew (see above). One child (2.7%) died in 5th
month of TCZ therapy due to severe uncontrolled MAS.
In patients who developed MAS we had used a combin-
ation of corticosteroids, IVIG and TCZ treatment.
In children who achieved inactive disease by our evalu-
ation, were successfully weaned off of corticosteroids, CsA
and MTX, and had at least a 12 month TCZ course, we
tried to initiate a gradual taper of the TCZ. At first we
elongated period between infusions. We increased the
interval between infusions up to 5 weeks during the next
3–4 months, then did infusions every 6 weeks during the
next 3 months. If at that point, the patient had no any
clinical and laboratory signs of SoJIA disease activity, TCZ
therapy was stopped. In some patients MTX was discon-
tinued before TCZ was stopped but in other patients
MTX was continued during TCZ tapering and after the
TCZ treatments were discontinued.
Only an attending physician could decide whether to
stop the MTX. Usually this decision to continue or stop
the MTX was based on the number of active joints at the
start of TCZ, the presence of erosions at onset of TCZ
treatment and how long the delay was between SoJIA on-
set and the start of the TCZ. At the end of this study, 7/33
(21.2%) patients were in a TCZ remission (4/7 remission
off all medications, 3/7 in remission but still on MTX).
The median time in remission for those off of all medica-
tions including TCZ was 1078 days (IQR: 848–1217) days.
For the children off of TCZ but still on MTX, the median
duration 918 days (IQR: 508–1078).
The longest period of time off TCZ and in remission
in our cohort was 1467 days. Also we have another 5/12
children who started TCZ later in our study, who have
achieved inactive disease, and currently receive TCZ
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Demographics and outcomes are in Table 1.
A comparison of clinical and laboratory features
between patients with Q2W and Q4W group are in the
Table 2. We have not found any differences between
both groups in gender distribution, and frequency of CS,
MTX and CsA usage. Also there were no differences in
such SoJIA-related signs and symptoms as fever, rash,
and lymphadenopathy. As suspected, patients who were
treated every 4 weeks had typically a higher Hb, total
protein, albumin as well as a lower WBC, % granulo-
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*Fisher’s exact test, **the data analysis was performed on 25 patients (1 withdrew d
the MAS (MAS before TCZ and after)The main interesting things were different outcomes
in patients depending on activity. Patients from Q4W
group were more susceptible to IL-6 blockade and had
higher TCZ efficacy. All reached inactive disease and
discontinued TCZ due to remission were from this
group. No new cases of macrophage activation syndrome
(MAS) were seen in the Q4W group as well as a lower
frequency of organ involvement and relapses during
TCZ treatment. Also, in the Q4W group, CS and MTX
were discontinued more frequently and sooner com-
pared to Q2W patients (HR = 2.9, p = 0.0003- Data in
Table 2 and Figure 2). Only 1 child in the Q4W groupere treated every 2 and every 4 weeks
Q2W (n =11) Q4W (n =26) р
seline
9.8 (8.16; 11.6) 11,4 (10,8; 13,0) 0,006
9 (81.8) 12 (46,2) 0,07*
17.2 (12.8; 20.8) 9,85 (7,8; 13,8) 0,008
11.6 (8.2; 19.0) 7.6 (5.2; 11.9) 0.05
3728 (10112; 18654) 6445 (4914; 8787) 0,002
8944 (6560; 15390) 3314 (1840; 7240) 0,005
8925 (7700; 10332) 3408 (2907; 3975) 0.01
100.0 (20.6; 120.0) 18.0 (10.3; 74.5) 0.01
46.0 (42.0; 63.0) 25.5 (12.0; 50.0) 0.01
287.0 (326.0; 3509.0) 128.0 (51.0; 224.0) 0.0006
714.0 (635.0; 796.0) 464.0 (423.0; 513.0) 0.006
6.7 (6.2; 7.0) 7.2 (6.8; 7.8) 0.004
2.1 (1.8; 2.5) 3.1 (2.9; 3.3) 0.0003
10 (90.9) 10 (38.5) 0.003
6 (54.6) 5 (19.2) 0.05
5 (45.5) 8 (30.8) 0.47
4 (36.3) 0 (0.0) 0.005*
5 (45.5) 1 (3.9) 0.005*
6 (54.6) 4 (15,4) 0.04*
6 (54.6) 0 (0.0) 0.0001*
7 (63.6) 5 (19.2) 0.018*
5 (45.5)*** 0 (0.0) 0.001*
g TCZ course
2/7 (28.6) 19/19 (100.0) 0.0001*
167.0 (94.0; 237.0) 62.0 (34.0; 93.0) 0.005
1/8 (12.5) 8/24 (33.3) 0.39*
3/7 (42.9) 8/13 (61.5) 0.64*
5 (45.5) 2 (7.7) 0.016*
5 (45.5)*** 0 (0.0) 0.001*
0 (0.0) 12/25** (48.0) 0.03*
0 (0.0) 7/25** (28.0) 0.15*
ue to infusion reaction), ***the same patients whom TCZ was initiated during
Figure 2 Cumulative probability corticosteroid discontinuation
in different TCZ regimens (Q2W vs. Q4W) between patients
with Q4W and Q2W.
Table 3 The cut-offs of clinical and laboratorial parameters
of SJIA patients treated Q4W
Parameter OR (95%CI) AUC** (95%CI) p
Hemoglobin > 10.3 g/dl 32.0 (4.5; 227.2) 0.75 (0.57-0.88) 0.0001*
Granulocytes ≤ 9792 cells in
1 μl
24.8 (3.8; 160.0) 0.85 (0.68; 0.95) 0.0001*
WBC in 1 week ≤ 10.1*109/l 6.9 (1.3; 37.2) 0.7 (0.49; 0.86) 0.027*
Granulocytes in 1 week≤ 8142
cells in 1 μl
21.3 (2.9; 154.6) 0.82 (0.62-0.94) 0.001*
WBC in 2 weeks≤ 7.5*109/l 12.2 (2.1; 71.0) 0.66 (0.38; 0.88) 0.003*
Granulocytes in 2 weeks≤ 3975
cells in 1 μl
28.0 (2.1; 379.3) 0.8 (0.52-0.96) 0.0015*
Platelets > 208 *109/l 20.8 (2.0; 213.0) 0.64 (0.46; 0.8) 0.005*
CRP≤ 82.2 mg/l 19.6 (3.3; 117.5) 0.77 (0.59-0.9) 0.001*
ESR≤ 26 mm/h 28.4 (4.8; 168.3) 0.76 (0.58-0.89) 0.001*
Ferritin≤ 605 mg/ml 89.9 (4.2; 1940.6) 0.86 (0.67-0.96) 0.0001*
LDH≤ 571 U/l 42.0 (3.8; 469.1) 0.8 (0.58-0.94) 0.001*
Total protein > 7.2 g/dl 10.0 (1.1; 89.8) 0.75 (0.57-0.88) 0.027*
Albumin > 2.8 g/dl 46.0 (5.5; 382.7) 0.87 (0.7-0.96) 0.0001*
No splenomegaly 5.0 (1.1; 23.4) - 0.05*
No hepatomegaly 31.8 (1.5; 659.6) - 0.003
No coagulopathy 31.8 (1.5; 659.6) - 0.005*
No ILD 20.8 (2.0; 213.0) - 0.005*
No cardiac involvement 6.6 (1.3; 32.5) - 0.04*
No CNS dysfunction 62.6 (3.1; 1282.9) - 0.0001*
No kidney involvement 31.8 (1.5; 659.6) - 0.005*
No MAS during TCZ 44.8 (2.2; 918.5) - 0.01*
* Fisher’s exact test, ** AUC – area under the curve.
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between TCZ infusions; We were able to re-start TCZ at
q 4 weeks with the same efficacy as the first course.
No patients who required TCZ every 2 weeks ex-
perienced TCZ-free remission at the end of the study. Also,
patients who required TCZ Q2W had MAS, hepatomegaly,
splenomegaly, cardio-respiratory involvement, CNS dys-
function and coagulopathy more frequently than patients
treated with TCZ Q4W. All cases of MAS relapses during
TCZ therapy (only 1 relapse per patient) were in the Q2W
group which likely reflects the severity of these patients.
We have found differences in the decrease of the %
granulocytes at 1 week after the 1st TCZ infusion be-
tween the Q4W and the Q2Wgroups. Patients treated
with Q4W TCZ decreased the granulocyte number by a
factor of 2 while patients treated Q2W decreased the
granulocytes by a factor of only 1.5. Possibly this differ-
ence in the decrease of the granulocytes may reflect the
greater susceptibility to TCZ of the Q4W SoJIA patients.
Patients from the Q4W group of patients also had less
frequent infusion reactions.
As suspected, all patients who successfully discontin-
ued TCZ were from the Q4W group and tolerated TCZ
infusions every 4 weeks without relapse. One Q4W
patient who had been off TCZ in remission for 1085 days
experienced a relapse of the SoJIA and required a sec-
ond course of TCZ with renewed efficacy. The clinical
and laboratorial parameters of SJIA patients treated
Q4W are in Table 3.
For selection of diagnostic criteria which can more
accurately predict which patients might require Q2W
TCZ rather than Q4W TCZ .
The clinical variables were:
1) Absence of hepatomegaly;2) Coagulopathy;
3) CNS dysfunction; and
4) Interstitial lung disease;
The laboratory variables included:
1) Ferritin ≤ 605 μg/l,
2) LDH ≤ 571 U/l,
3) Albumin > 2.8 g/dl,
4) ESR ≤ 26 mm/h,
5) Granulocytes ≤9792 cells in 1 μl,
6) Hemoglobin > 10.3 g/dl,
7) Platelets > 208*109/l,
8) CRP ≤ 82.2 mg/l.
We evaluated separately the clinical and laboratory
variables as well as combinations. We calculated sensitivity,
specificity and OR for each combination. After this analysis,
we found that only clinical variables and their combination
(any 2 or moreclinical variables) had comparatively low
OR - 44.8 (2.2 - 918.5), with low sensitivity level −0.45.
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ation of Q4W then clinical characteristics. Any 4 or more
laboratory criteria provided the highest specificity (1.0)
and sensitivity (1.0) with highest OR – 1219.0 (22.8 –
65278.4) in the model. Any attempt to combine clinical
variables with laboratory did not change sensitivity, speci-
ficity and mean of OR. Thus laboratory data in our pa-
tients appears to be more useful for predicting the
patients with SoJIA who did well onQ4W rather than
Q2W. Also we summarized the provisional clinical signs
and laboratory parameters (risk factors) before 1st TCZ
infusion which may increase the future probability of
reaching remission off TCZ (Table 4): no fever before TCZ
initiation, no MAS after start of TCZ, no lymphadenop-
athy, absence of coagulopathy and CNS dysfunction and
low disease activity, allowed to use TCZ every 4 weeks.
Discussion
TCZ (an anti-IL-6) is one of the new biologic drugs that
has been approved in some countries for treatment of
SoJIA patients as young as 2 years. Another effective
class of biologics, which shows a similar efficacy, is the
Il-1 blockers.
Unfortunately, in some countries such as Russia, the
IL-1 blockers are still unavailable in 2014 and TCZ is
the only biologic option in treatment of SoJIA. Accord-
ing to the results of two published randomized control
trials, treatment with TCZ can achieve inactive disease
in more than 1/3 patients with SoJIA [4-6].
Improvement in SoJIA course or achievement status of
inactive disease allows to the tapering and often discon-
tinuation of CS and DMARDS. It is known that patients
with SoJIA are variable in disease course and severity.
The SoJIA disease courses range from a benign mono-
cyclic course with mild arthritis to a relapsing and per-
sistent course with severe articular and extra-articularTable 4 Parameters, associated with achievement TCZ-off
remission (Cox regression model)
Risk factor Hazard ratio P-value§
Fever before TCZ initiation: no
(reference category: yes)
3.15 0.02
MAS after TCZ initiation: no
(reference category: yes)
30.5 0.015
Lymphadenopathy before TCZ initiation: no
(reference category: yes)
2.6 0.04
Coagulopathy before TCZ initiation: no
(reference category: yes)
30.5 0.015
CNS dysfunction before TCZ initiation: no
(reference category: yes)
3.8 0.04
Low diseases activity: TCZ Q2W
(reference category: Q4W)
0.22 0.004
Event of interest: achievement TCZ-off remission. Complete data were available
for 33 patients.
§P values refer to the Wald’s chi2-test.damage [20]. These different disease courses are the
basis for choosing different treatment strategies. The-
milder patients usually require small doses of NSAIDs
and CS while severe patients need higher doses of CS
and deep and prolonged immunosuppression [21]. In
the study of M. Gattorno et al., it was shown that there
appeared to be 2 subsets of SoJIA patients with different
response on Il-1 blockade. One subset of patients, who
had more systemic features and had fewer active joints,
appeared to have a better response to the Il-1 medica-
tion [22].
Our idea was similar. Children with SoJIA may well have
different treatment responses to TCZ, and we set out to
find the group of patients which might be more responsi-
veto TCZ treatment.
The dosage and regimen of TCZ appears to depend on
the disease itself and the disease pathogenesis. Children
with Castleman’s disease require a TCZ dosage of 8 mg/kg
weekly because in this systemic diseaselymphocytes and
macrophages of the affected lymph nodes continuously
produce IL-6 [23,24].
It is useful to compare SoJIA to adult rheumatoid arth-
ritis (RA). In children with SoJIA, a very impressive sys-
temic inflammation occurs, presumably provided by cells
of innate immunity of bone marrow origin. In adult RA,
IL-6 is produced by synoviocytes in the inflamed joints.
The IL-6 is part of a group of inflammatory cytokines pro-
duced in RA such as TNF-α, IL-1β, and other cytokines.
RA appears to be more a restricted and not as a systemic
inflammatory disease targeting more the joints than other
organs, at least compared to SoJIA. In RA, TCZ is able to
be infused at an every 4-week interval [25].
The extent of immunological activation appears to be
more potent in SoJIA compared to RA, which supports
the rationale to use TCZ Q2W in very active, systemic-
ally ill SoJIA patients. Indeed, as the pathophysiological
background of each disease appears to be very different,
the justification for different infusion intervals is clear.
The previous data about the pharmacokinetics of TCZ
in SoJIA have shown the efficacy after a single TCZ admin-
istration in doses ranging from 2 to 12 mg/kg, with contin-
ued effectiveness up to 8 weeks after a dose [11]. Also
there is data supporting the effectiveness of even lower
doses of TCZ: 8 mg/kg instead of 12 mg/kg and 4 mg/kg
instead of 8 mg/kg. It has also been shown that the time
between infusions could be increased up to 3 weeks the
without TCZ failure [26]. One of our aims was to distin-
guish the subgroup of patients with a milder SoJIA course
and a higher responsiveness to TCZ for whom TCZ treat-
ment every 4 weeks will be quite effective.
For the lower disease activity group, or mild SoJIA,
TCZ infused every 4 weeks may well be sufficient. These
patients will be also treated with the conventional proto-
col such as the low-dose corticosteroid management, or
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course type.
One weakness of our study is that identification of the
low disease activity SoJIA group is problematic as patients
often receive concomitant anti-rheumatic treatment, such
as CS, MTX, and CsA, before entering into the toci-
lizumab treatment. Whether the lower disease activity
group really exists, or their disease activity was lowered by
the previous treatment,or both, is hard to distinguish and
may influence our judgment on the efficacy of tocilizumab
in each patient. Yet in our trial there were impressive dif-
ferences that support the reality of a lower disease activity
group. In the patient group with low disease activity who
were treated every 4 weeks, we could decrease CS more
frequently and faster, had less frequency of relapses, had
better response rates, more quickly achieved a status of
inactive disease and TCZ-free remission. We believe that
these treatment responses and outcomes support the like-
lihood of a low disease activity group in our SoJIA patients
at our center.
The elongation of intervals between infusions without
failure of efficacy has a lot of benefits. We have to be
aware of the cost-benefit ratio. Also, less frequent infu-
sions improves the patient’s and family’s quality of life with
less frequent outpatient infusions or hospital infusions.
There are other limitations of our study. It is a non-
blinded retrospective cohort study with all the limitations
of such a study. In any single center’s experience with TCZ,
there is a problem with a smaller sample size which may
bias our results. The observation period after the TCZ
infusions is also relatively short. These criteria are useful for
our patients and it remains to be seen if it proves useful in
larger series of patients and at other centers.
Conclusions
In our study we have shown a comparative efficacy of
different TCZ protocols based on clinical heterogeneity of
SoJIA patients. We offer a set of provisional criteria that
may help differentiate patients with favorable and unfa-
vorable disease courses and allow TCZ treatment every
4 weeks for the patients with the more favorable prognosis
instead of the more aggressive every 2 week regimen. Our
criteria may help increase the probability of a child with
SoJIA reaching remission off of TCZ without the expense
and potential side-effects of using TCZ every 2 weeks.
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